Brief: Scynexis Announces FDA Approval Of Second Indication For Brexafemme® (Ibrexafungerp Tablets) For Reduction In Incidence Of Recurrent Vulvovaginal Candidiasis

Scynexis

01/12/2022 13:03

Dec 1 (Reuters) - SCYNEXIS Inc  SCYX.O :
    * SCYNEXIS ANNOUNCES FDA APPROVAL OF SECOND INDICATION FOR
BREXAFEMME® (IBREXAFUNGERP TABLETS) FOR REDUCTION IN INCIDENCE
OF RECURRENT VULVOVAGINAL CANDIDIASIS
    * SCYNEXIS ANNOUNCES FDA APPROVAL OF SECOND INDICATION FOR
BREXAFEMME® (IBREXAFUNGERP TABLETS) FOR REDUCTION IN INCIDENCE
OF RECURRENT VULVOVAGINAL CANDIDIASIS

Source text for Eikon:  ID:nGNX32zdsC 
Further company coverage:  SCYX.O 
 ((Reuters.Briefs@thomsonreuters.com;;))